Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H2 2018

  • ID: 4590362
  • Drug Pipelines
  • 134 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AptaTargets SL
  • Bioleaders Corp
  • Eisai Co Ltd
  • Formune SL
  • GlaxoSmithKline Plc
  • Immune Design Corp
  • MORE
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H2 2018

Summary:

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Toll-like receptor 4 is a protein encoded by the TLR4 gene. This receptor is mostly expressed in placenta, and in myelomonocytic subpopulation of the leukocytes. It is involved in LPS-independent inflammatory responses triggered by free fatty acids, such as palmitate, and Ni2+. It responses are triggered by Ni2+ require non-conserved. In complex with TLR6 promotes sterile inflammation in monocytes in response to oxidized low-density lipoprotein (oxLDL).

Toll Like Receptor 4 (hToll or CD284 or TLR4) pipeline Target constitutes close to 44 molecules. Out of which approximately 34 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 9, 4, 16 and 4 respectively.

Similarly, the universities portfolio in Preclinical and Discovery stages comprises 8 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease, Gastrointestinal, Central Nervous System, Immunology, Cardiovascular, Dermatology, Ear Nose Throat Disorders, Genito Urinary System And Sex Hormones, Respiratory, Mouth and Dental Disorders, Musculoskeletal Disorders, Ophthalmology and Other Diseases which include indications Non-Alcoholic Steatohepatitis (NASH), Autoimmune Hepatitis, Inflammation, Liver Fibrosis, Sepsis, Atherosclerosis, Atopic Dermatitis, Breast Cancer, Dengue Fever, Drug Addiction, Kidney Fibrosis, Rheumatoid Arthritis, Soft Tissue Sarcoma, Traumatic Brain Injury, Acute Ischemic Stroke, Acute Liver Failure, Acute Lung Injury, Acute Pain, Alcohol Addiction, Amyotrophic Lateral Sclerosis, Autoimmune Disorders, Bacterial Sepsis, Burns, Cervical Cancer, Chronic Back Pain, Chronic Liver Disease, Complicated Intra-Abdominal Infections, Crohn's Disease (Regional Enteritis), Ebolavirus Infections (Ebola Hemorrhagic Fever), Endotoxemia, Epilepsy, Escherichia coli Infections, Follicular Lymphoma, Globoid Cell Leukodystrophy (Krabbe Disease), Hearing Disorders, Human Papillomavirus (HPV) Associated Cancer, Inflammatory Bowel Disease, Ischemia Reperfusion Injury, Keratoconjunctivitis sicca (Dry Eye), Leishmaniasis (Kala-Azar), Listeriosis, Low Back Pain, Lung Cancer, Marburgvirus Infections (Marburg Hemorrhagic Fever), Melanoma, Merkel Cell Carcinoma, Metastatic Melanoma, Migraine, Multiple Sclerosis, Necrotizing Enterocolitis, Neuropathic Pain, Non Alcoholic Fatty Liver Disease (NAFLD), Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Opium (Opioid) Addiction, Opium Withdrawal Syndrome, Osteoarthritis, Ovarian Cancer, Pain, Pancreatic Cancer, Peanut Allergy, Phlebovirus Infections, Post-Traumatic Stress Disorder (PTSD), Postherpetic Neuralgia, Primary Progressive Multiple Sclerosis (PPMS), Prostate Cancer, Pseudomonas aeruginosa Infections, Pulmonary Edema, Pulmonary Inflammation, Recurrent Glioblastoma Multiforme (GBM), Rhinitis, Rosacea, Secondary Progressive Multiple Sclerosis (SPMS), Septic Shock, Solid Tumor, Trauma, Wounds, Xerostomia and Zika Virus Infections.

The latest report Toll Like Receptor 4 - Pipeline Review, H2 2018, outlays comprehensive information on the Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 4 (hToll or CD284 or TLR4)
  • The report reviews Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Toll Like Receptor 4 (hToll or CD284 or TLR4)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Toll Like Receptor 4 (hToll or CD284 or TLR4) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AptaTargets SL
  • Bioleaders Corp
  • Eisai Co Ltd
  • Formune SL
  • GlaxoSmithKline Plc
  • Immune Design Corp
  • MORE
Introduction

Report Coverage

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Overview

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Companies Involved in Therapeutics Development

AptaTargets SL

Batu Biologics Inc

Bioleaders Corp

Cyxone AB

Eisai Co Ltd

eTheRNA Immunotherapies NV

EyeGene Inc

Formune SL

GigaGen Inc

GlaxoSmithKline Plc

Harbor Therapeutics Inc

Immune Design Corp

Immunovo BV

Kyorin Pharmaceutical Co Ltd

NovImmune SA

Sanofi

TaiwanJ Pharmaceuticals Co Ltd

Takeda Pharmaceutical Co Ltd

Vascular Biogenics Ltd

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Drug Profiles

(clonidine + naltrexone) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ApTOLL - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AyuV-25 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Biologic to Agonize TLR4 for Drug Addiction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Biologics to Antagonize TLR4 for Dengue Fever - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BLSH-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C-34 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CIA-05 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CMB-305 + G-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CRX-526 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DMT-210 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ECF-843 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ECI-006 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EDA-HPVE7 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

eritoran tetrasodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

G-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Inhibit TLR4 for Acute Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-1795091 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HE-3286 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hp-91 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ibudilast - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ISAS-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Agonize TLR4 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nalmefene - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naltrexone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naltrexone hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NI-0101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P-13 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P-16 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P-7 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P-MAPA - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PEPA-10 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rabeximodum - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

resatorvid - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAR-439794 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize TLR2 and TLR4 for Pulmonary Edema, Inflammation and Sepsis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize TLR4 for Acute Lung Injury and Bacterial Sepsis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize TLR4 for Dengue Fever - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Antagonize TLR4 for Sepsis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to target TLR-4 for Oncology, Inflammation and Infectious Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TJC-0133 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VB-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VB-703 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Dormant Products

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Discontinued Products

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Product Development Milestones

Featured News & Press Releases

Jun 25, 2018 : Immune Design Presents Data on the Mechanism of Action of G100 via TLR4 Expressed in B Cell Malignancies at the Inaugural AACR International Meeting Advances in Malignant Lymphoma

May 24, 2018 : eTheRNA Enrols First Patient in High Dose Cohort of Phase 1b study of TriMix mRNA-based Cancer Specific Immunotherapy (ECI-006) in Melanoma

May 09, 2018 : MediciNova Announces Opening of Investigational New Drug Application for MN-166 (ibudilast) in Glioblastoma

May 07, 2018 : MediciNova Announces Plans to Collaborate with UCLA Researchers in Grant-Funded Clinical Trial of MN-166 (ibudilast) in Alcohol Use Disorder and Withdrawal

Apr 26, 2018 : MediciNova Announces Additional Data from Completed Clinical Trial of MN-166 (ibudilast) in ALS Presented at the American Academy of Neurology 70th Annual Meeting

Apr 24, 2018 : MediciNova Announces the Presentation of the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS at the American Academy of Neurology (AAN) 70th Annual Meeting Plenary Session with Additional Imaging Data

Mar 29, 2018 : MediciNova Announces Results of Phase 2 Clinical Trial of MN-166 (ibudilast) in Methamphetamine Dependence

Mar 19, 2018 : eTheRNA completes enrolment of low dose cohort for Phase 1b study of TriMix mRNA-based cancer specific immunotherapy (ECI-006) in melanoma

Mar 12, 2018 : Immune Design Reports Data Update for Lead Immunotherapy Program: Increased Objective Responses for G100/pembrolizumab Combination in Follicular Lymphoma

Feb 18, 2018 : MediciNova Announces Upcoming Presentation of the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS at the American Academy of Neurology 70th Annual Meeting

Feb 01, 2018 : MediciNova Announces MN-166 (ibudilast) Demonstrated a 26% Reduction in Confirmed Disability Progression in the SPRINT-MS Phase 2b Trial in Progressive MS: Potential Best-in-Disease Drug

Jan 31, 2018 : MediciNova Announces Presentation of the SPRINT-MS Phase 2b Study of MN-166 (ibudilast) in Progressive MS at the ACTRIMS Forum

Jan 30, 2018 : MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the American Academy of Neurology 70th Annual Meeting in Los Angeles, California

Dec 10, 2017: Combination of G100 with KEYTRUDA (pembrolizumab) Triggers Robust Systemic Responses in Follicular NHL Patients

Dec 07, 2017: MediciNova Announces Positive Top-Line Results from the Clinical Trial of MN-166 (ibudilast) in ALS

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indications, H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..2), H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..3), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1)

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Companies, H2 2018 (Contd..3), H2 2018

Number of Products under Investigation by Universities/Institutes, H2 2018

Products under Investigation by Universities/Institutes, H2 2018

Products under Investigation by Universities/Institutes, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by AptaTargets SL, H2 2018

Pipeline by Batu Biologics Inc, H2 2018

Pipeline by Bioleaders Corp, H2 2018

Pipeline by Cyxone AB, H2 2018

Pipeline by Eisai Co Ltd, H2 2018

Pipeline by eTheRNA Immunotherapies NV, H2 2018

Pipeline by EyeGene Inc, H2 2018

Pipeline by Formune SL, H2 2018

Pipeline by GigaGen Inc, H2 2018

Pipeline by GlaxoSmithKline Plc, H2 2018

Pipeline by Harbor Therapeutics Inc, H2 2018

Pipeline by Immune Design Corp, H2 2018

Pipeline by Immunovo BV, H2 2018

Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2018

Pipeline by NovImmune SA, H2 2018

Pipeline by Sanofi, H2 2018

Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H2 2018

Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018

Pipeline by Vascular Biogenics Ltd, H2 2018

Dormant Products, H2 2018

Dormant Products, H2 2018 (Contd..1), H2 2018

Dormant Products, H2 2018 (Contd..2), H2 2018

Dormant Products, H2 2018 (Contd..3), H2 2018

Discontinued Products, H2 2018

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AptaTargets SL
  • Batu Biologics Inc
  • Bioleaders Corp
  • Cyxone AB
  • Eisai Co Ltd
  • eTheRNA Immunotherapies NV
  • EyeGene Inc
  • Formune SL
  • GigaGen Inc
  • GlaxoSmithKline Plc
  • Harbor Therapeutics Inc
  • Immune Design Corp
  • Immunovo BV
  • Kyorin Pharmaceutical Co Ltd
  • NovImmune SA
  • Sanofi
  • TaiwanJ Pharmaceuticals Co Ltd
  • Takeda Pharmaceutical Co Ltd
  • Vascular Biogenics Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll